Ignite Creation Date:
2024-05-06 @ 1:52 PM
Last Modification Date:
2024-10-26 @ 1:21 PM
Study NCT ID:
NCT04140487
Status:
RECRUITING
Last Update Posted:
2024-07-03
First Post:
2019-08-19
Brief Title:
Azacitidine Venetoclax and Gilteritinib in Treating Patients With RecurrentRefractory FLT3-Mutated Acute Myeloid Leukemia Chronic Myelomonocytic Leukemia or High-Risk Myelodysplastic SyndromeMyeloproliferative Neoplasm
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Refractory MyelodysplasticMyeloproliferative Neoplasm |
| Recurrent Acute Myeloid Leukemia |
| Recurrent Chronic Myelomonocytic Leukemia |
| Recurrent MyelodysplasticMyeloproliferative Neoplasm |
| Refractory Acute Myeloid Leukemia |
| Refractory Chronic Myelomonocytic Leukemia |
Keywords: